Catalent, Inc. (CTLT)
Largest Insider Buys in Sector
CTLT Stock Price History Chart
CTLT Stock Performance
About Catalent, Inc.
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary …
Insider Activity of Catalent, Inc.
Over the last 12 months, insiders at Catalent, Inc. have bought $0 and sold $1.57M worth of Catalent, Inc. stock.
On average, over the past 5 years, insiders at Catalent, Inc. have bought $671,930 and sold $326.93M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,000 shares for transaction amount of $49,980 was made by Ryan Michelle R (director) on 2023‑08‑31.
List of Insider Buy and Sell Transactions, Catalent, Inc.
| 2024-11-11 | Sale | director | 2,800 0.0015% | $59.70 | $167,160 | +3.54% | ||
| 2024-10-18 | Sale | SVP, General Counsel, CCO | 320 0.0002% | $59.97 | $19,190 | +0.95% | ||
| 2024-09-26 | Sale | Group President, Biologics | 1,994 0.0011% | $59.97 | $119,580 | +0.53% | ||
| 2024-08-02 | Sale | Group Pres. Pharma & Consumer | 1,169 0.0006% | $59.55 | $69,614 | +1.03% | ||
| 2024-08-02 | Sale | SVP, Quality & Reg. Affairs | 666 0.0004% | $59.55 | $39,660 | +1.03% | ||
| 2024-08-02 | Sale | SVP, Chief HR Officer | 3,859 0.0021% | $59.67 | $230,267 | +1.03% | ||
| 2024-08-02 | Sale | Pres. BioProduct Delivery, CoS | 662 0.0004% | $59.56 | $39,429 | +1.03% | ||
| 2024-08-02 | Sale | SVP, General Counsel, CCO | 608 0.0003% | $59.58 | $36,225 | +1.03% | ||
| 2024-07-29 | Sale | President & CEO | 9,088 0.005% | $58.76 | $534,011 | +2.02% | ||
| 2024-07-29 | Sale | Group Pres. Pharma & Consumer | 349 0.0002% | $58.70 | $20,486 | +2.02% | ||
| 2024-07-29 | Sale | SVP, Quality & Reg. Affairs | 283 0.0002% | $58.69 | $16,609 | +2.02% | ||
| 2024-07-29 | Sale | Pres. BioProduct Delivery, CoS | 206 0.0001% | $58.67 | $12,086 | +2.02% | ||
| 2024-07-08 | Sale | SVP, Chief Financial Officer | 2,993 0.0017% | $56.74 | $169,823 | 0.00% | ||
| 2024-06-04 | Sale | Pres. BioProduct Delivery, CoS | 1,401 0.0008% | $54.26 | $76,023 | +8.74% | ||
| 2024-03-15 | Sale | SVP, Quality & Reg. Affairs | 387 0.0002% | $56.20 | $21,749 | +4.25% | ||
| 2023-08-31 | director | 1,000 0.0006% | $49.98 | $49,980 | +9.95% | |||
| 2023-08-30 | Executive Chair | 21,000 0.012% | $50.24 | $1.06M | +12.17% | |||
| 2023-08-24 | Sale | Group Pres. Pharma & Consumer | 396 0.0002% | $44.49 | $17,618 | +22.22% | ||
| 2023-08-24 | Sale | President & CEO | 2,071 0.0011% | $44.54 | $92,245 | +22.22% | ||
| 2023-08-24 | Sale | EVP & Chief Admin Officer | 817 0.0004% | $44.65 | $36,479 | +22.22% |
Insider Historical Profitability
| Ryan Michelle R | director | 10835 0.006% | $63.48 | 1 | 1 | |
| MOREL DONALD E JR | director | 46958 0.0259% | $63.48 | 3 | 0 | +15.26% |
| BUZY PETER L | President, Gene Therapy | 44500 0.0245% | $63.48 | 1 | 0 | +17.25% |
| GREISCH JOHN J | Executive Chair | 34000 0.0187% | $63.48 | 2 | 0 | +20.08% |
| Roehrhoff Uwe | director | 16489 0.0091% | $63.48 | 1 | 0 | +6.41% |
Institutional Investor Ownership
| The Vanguard Group | $1.15B | 11.28 | 20.41M | +1.08% | +$12.34M | 0.02 | |
| BlackRock | $857.85M | 8.4 | 15.2M | -6.05% | -$55.29M | 0.02 | |
| Capital World Investors | $729.58M | 7.14 | 12.92M | -32.26% | -$347.48M | 0.12 | |
| Nomura Holdings | $635.69M | 6.22 | 11.26M | -1.97% | -$12.77M | 5.55 | |
| Janus Henderson | $539.7M | 5.28 | 9.56M | -27.84% | -$208.22M | 0.27 |